The insurance value of medical innovation

Journal of Public Economics

Volumn 145, Issue , 2017, Pages 94-102

  Lakdawalla, Darius ^a,c   Malani, Anup ^b,c   Reif, Julian ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cost benefit analysis; Health insurance; Medical innovation; Value of health

Indexed keywords

EID: 84999837794     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpubeco.2016.11.012     Document Type: Article

References (39)

1. Abaluck, J., Gruber, J., Choice inconsistencies among the elderly: evidence from plan choice in the Medicare part D program. Am. Econ. Rev., 2011, 1180–1210.
2. Acemoglu, D., Cutler, D., Finkelstein, A., Linn, J., Did medicare induce pharmaceutical innovation?. Am. Econ. Rev. 96:2 (2006), 103–107.
3. Anon, New 50 million cancer fund already intellectually bankrupt. Lancet, 376(9739), 2010, 389.
4. Baicker, K., Taubman, S.L., Allen, H.L., Bernstein, M., Gruber, J.H., Newhouse, J.P., Schneider, E.C., Wright, B.J., Zaslavsky, A.M., Finkelstein, A.N., The Oregon experiment—effects of Medicaid on clinical outcomes. N. Engl. J. Med. 368:18 (2013), 1713–1722.
5. Barcellos, S.H., Jacobson, M., The effects of Medicare on medical expenditure risk and financial strain. Am. Econ. J. Econ. Pol. 7:4 (2015), 41–70.
6. Barsky, R.B., Juster, F.T., Kimball, M.S., Shapiro, M.D., Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. Q. J. Econ. 112:2 (1997), 537–579.
7. Blume-Kohout, M.E., Sood, N., Market size and innovation: effects of Medicare part D on pharmaceutical research and development. J. Public Econ. 97 (2013), 327–336.
8. Caves, R.E., Whinston, M.D., Hurwitz, M.A., Pakes, A., Temin, P., Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity Microeconomics, 1991, 1991, 1–66.
9. Chetty, R., A new method of estimating risk aversion. Am. Econ. Rev. 96:5 (2006), 1821–1834.
10. Clemens, J., The Effect of US Health Insurance Expansions on Medical Innovation. 2013, National Bureau of Economic Research.
11. Cohen, A., Einav, L., Estimating risk preferences from deductible choice. Am. Econ. Rev. 97:3 (2007), 745–788.
12. Cutler, D.M., Your Money or your Life: Strong Medicine for America's Health Care System. 2005, Oxford University Press, USA.
13. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G.L., Methods for the economic evaluation of health care programmes. OUP Catalogue, 2005.
14. Engelhardt, G.V., Gruber, J., Medicare part D and the financial protection of the elderly. Am. Econ. J. Econ. Pol. 3:4 (2011), 77–102.
15. Ehrlich, I., Becker, G.S., Market insurance, self-insurance, and self-protection. J. Polit. Econ. 80:4 (1972), 623–648.
16. Finkelstein, A., McKnight, R., What did Medicare do? The initial impact of Medicare on mortality and out of pocket medical spending. J. Public Econ. 92:7 (2008), 1644–1668.
17. Goddeeris, J.H., Medical insurance, technological change, and welfare. Econ. Inq. 22:1 (1984), 56–67.
18. Green, C., Gerard, K., Exploring the social value of health-care interventions: a stated preference discrete choice experiment. Health Econ. 18:8 (2009), 951–976.
19. Hendren, N., Knowledge of Future Job Loss and Implications for Unemployment Insurance. 2015, National Bureau of Economic Research.
20. Jena, A.B., Philipson, T.J., Cost-effectiveness analysis and innovation. J. Health Econ. 27:5 (2008), 1224–1236.
21. Kocherlakota, N.R., The equity premium: it's still a puzzle. J. Econ. Lit. 34:1 (1996), 42–71.
22. Kowalski, A.E., What Do Longitudinal Data on Millions of Hospital Visits Tell Us About the Value of Public Health Insurance as a Safety Net for the Young and Privately Insured?. 2015, National Bureau of Economic Research.
23. Lakdawalla, D., Sood, N., Health insurance as a two-part pricing contract. J. Public Econ. 102 (2013), 1–12.
24. Lakdawalla, D., Reif, J., Bauer, D., Mortality Risk, Insurance, and the Value of Life, Working Paper. 2016.
25. Linley, W.G., Hughes, D.A., Societal views on NICE, cancer drugs fund, and value based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 22:8 (2013), 948–964.
26. Loury, G.C., Market structure and innovation. Q. J. Econ., 1979, 395–410.
27. Malani, A., Philipson, T.J., Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets. 2011, National Bureau of Economic Research.
28. Mehra, R., Prescott, E.C., The equity premium: a puzzle. J. Monet. Econ., 1985.
29. Murphy, K.M., Topel, R.H., The value of health and longevity. J. Polit. Econ. 114:5 (2006), 871–904.
30. Newhouse, J.P., Medical care costs: how much welfare loss?. J. Econ. Perspect. 6:3 (1992), 3–21.
31. Nord, E., Richardson, J., Street, A., Kuhse, H., Singer, P., Maximizing health benefits vs egalitarianism: an Australian survey of health issues. Soc. Sci. Med. 41:10 (1995), 1429–1437.
32. Nordhaus, W.D., Invention Growth, and Welfare; a Theoretical Treatment of Technological Change. 1969, M.I.T. Press, Cambridge, Mass.
33. Philipson, T.J., Jena, A.B., Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum Health Econ. Policy, 9(2), 2006.
34. Philipson, T.J., Zanjani, G., Economic analysis of risk and uncertainty induced by health shocks: a review and extension. Handbook of the Economics of Risk and Uncertainty, 2014, 453.
35. Rosen, S., The value of changes in life expectancy. J. Risk Uncertain. 1:3 (1988), 285–304.
36. Shepard, D.S., Zeckhauser, R.J., Survival versus consumption. Manag. Sci. 30:4 (1984), 423–439.
37. Smith, J.P., Healthy bodies and thick wallets: the dual relation between health and economic status. J. Econ. Perspect. 13:2 (1999), 145–166.
38. Verguet, S., Laxminarayan, R., Jamison, D.T., Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. Health Econ., 2014.
39. Weisbrod, B.A., The health care quadrilemma: an essay on technological change, insurance, quality of care, and cost containment. J. Econ. Lit., 1991, 523–552.